Worg Pharmaceuticals Stock

Worg Pharmaceuticals is a clinical stage biopharmaceutical company developing new treatments for allergies and other diseases.

Sign up today and learn more about Worg Pharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Worg Pharmaceuticals Stock

Worg Pharmaceuticals is a clinical-stage biopharmaceutical company developing new treatments for allergies and other diseases. The company is building a pipeline for allergy and autoimmune diseases based on two technology platforms, PCFiT and Apitope, through internal development and external collaboration with flexible business models. Worg is also developing a platform for molecular allergy diagnosis.

Funding History

January 2021$200M
September 2022$400M
June 2023$1.1B

Management

Chairman & CEO

Andrew Xu

Chief Scientific Officer and Head of European Operations

Rainer Henning

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo